Clinical Trial Update: MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of MK-2206 in combination with endocrine therapy for metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Metastatic Breast Cancer | Phase 1 | Status: WITHDRAWN